Cargando…

Proteasome inhibitor bortezomib stabilizes and activates p53 in hematopoietic stem/progenitors and double-negative T cells in vivo

We have previously shown that proteasome inhibitor bortezomib stabilizes p53 in stem and progenitor cells within gastrointestinal tissues. Here, we characterize the effect of bortezomib treatment on primary and secondary lymphoid tissues in mice. We find that bortezomib stabilizes p53 in significant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xue, Yuezhen, San Luis, Boris, Dress, Regine J., Murad, Katzrin Binte Ahmad, Ginhoux, Florent, Barker, Nick, Lane, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2023
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068759/ https://www.ncbi.nlm.nih.gov/pubmed/36940336 http://dx.doi.org/10.1073/pnas.2219978120

Ejemplares similares

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
por: Boccadoro, Mario, et al.
Publicado: (2005)

Proteasome Inhibitor Bortezomib Ameliorates Intestinal Injury in Mice
por: Yanaba, Koichi, et al.
Publicado: (2012)

Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib
por: Gelman, Julia S., et al.
Publicado: (2013)

Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice
por: Goh, Amanda M., et al.
Publicado: (2015)

Irradiation Selects for p53-Deficient Hematopoietic Progenitors
por: Marusyk, Andriy, et al.
Publicado: (2010)

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib
por: Steverding, Dietmar, et al.
Publicado: (2009)

Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib
por: Schlesser, Camille, et al.
Publicado: (2022)

Proteasome inhibition by bortezomib: A left hook and a right punch
por: Roelofs, Jeroen
Publicado: (2015)

Effect of the specific proteasome inhibitor bortezomib on cancer‐related muscle wasting
por: Penna, Fabio, et al.
Publicado: (2015)

Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance
por: Wu, Yi-Xin, et al.
Publicado: (2016)

Combined Effect of Bortezomib and Menadione Sodium Bisulfite on Proteasomes of Tumor Cells: The Dramatic Decrease of Bortezomib Toxicity in a Preclinical Trial
por: Astakhova, Tatiana M., et al.
Publicado: (2018)

In HPV-Positive HNSCC Cells, Functional Restoration of the p53/p21 Pathway by Proteasome Inhibitor Bortezomib Does Not Affect Radio- or Chemosensitivity()()
por: Seltzsam, Steve, et al.
Publicado: (2018)

The ubiquitin–proteasome system as a molecular target in solid tumors: an update on bortezomib
por: Milano, A, et al.
Publicado: (2009)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

Hypoxia Enhances the Senescence Effect of Bortezomib—The Proteasome Inhibitor—On Human Skin Fibroblasts
por: Krętowski, Rafał, et al.
Publicado: (2014)

Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
por: Cerruti, Fulvia, et al.
Publicado: (2017)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

The Proteasome Inhibitor Bortezomib Induces Apoptosis and Activation in Gel-Filtered Human Platelets
por: Ghansah, Harriet, et al.
Publicado: (2021)

Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome
por: Moreira, Wilfried, et al.
Publicado: (2017)

Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors
por: Tran, Huy Minh, et al.
Publicado: (2020)

Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL(3)B
por: Reynolds, Jennifer M, et al.
Publicado: (2007)

Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs
por: MUJTABA, TASKEEN, et al.
Publicado: (2012)

Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome
por: Sridhar, Settu, et al.
Publicado: (2013)

The Protective Effects of the Proteasome Inhibitor Bortezomib (Velcade) on Ischemia-Reperfusion Injury in the Rat Retina
por: Chen, Fang-Ting, et al.
Publicado: (2013)

Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response
por: Nikesitch, N, et al.
Publicado: (2016)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017)

Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer
por: Taromi, Sanaz, et al.
Publicado: (2017)

Reporter PET Images Bortezomib Treatment-Mediated Suppression of Cancer Cell Proteasome Activity
por: Lee, Jin Hee, et al.
Publicado: (2018)

NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2022)

In situ Electrochemical Evaluation of the Interaction of dsDNA with the Proteasome Inhibitor Anticancer Drug Bortezomib
por: Bunea, Mihaela-Cristina, et al.
Publicado: (2023)

ATRT-01. UPREGULATION OF PROTEIN SYNTHESIS AND PROTEASOME DEGRADATION CONFERS SENSITIVITY TO PROTEASOME INHIBITOR BORTEZOMIB IN MYC-ATYPICAL TERATOID/RHABDOID TUMORS
por: Tran, Minh-Huy, et al.
Publicado: (2020)

P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis
por: Mahfoudhi, Emna, et al.
Publicado: (2016)

The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells
por: Voortman, Jens, et al.
Publicado: (2007)

Bortezomib, a Proteasome Inhibitor, Attenuates Angiotensin II-Induced Hypertension and Aortic Remodeling in Rats
por: Li, Shuai, et al.
Publicado: (2013)

The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1
por: Zeniya, Moko, et al.
Publicado: (2017)

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib
por: Manda, Sudhir, et al.
Publicado: (2020)

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P. G., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2ic55ao9bsdc7j7357mvl77f32